Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8352193 | PMC |
| http://dx.doi.org/10.1016/j.jaccao.2019.07.004 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Krebs von den Lungen-6 surveillance in immune checkpoint inhibitor-induced pneumonitis.
J Immunother Cancer
December 2024
Department of Pharmacy, Kyushu University Hospital, Fukuoka, Japan
Background: The immune-related adverse event (irAE), pneumonitis, is a potentially fatal complication of immune checkpoint inhibitors (ICIs). Preventing its progression is crucial, emphasizing the need for effective screening tests. We evaluated the feasibility of using Krebs von den Lungen-6 (KL-6), a marker for interstitial pneumonitis, as a screening tool for pneumonitis.
View Article and Find Full Text PDFImmune Checkpoint Inhibitor-Induced Myositis, Myocarditis, Myasthenia Gravis, and Autonomic Neuropathy Successfully Treated With Rituximab.
Muscle Nerve
January 2025
Department of Rheumatology, Graduate School of Medical and Dental Sciences, Institute of Science Tokyo, Tokyo, Japan.
Comparative study of management strategies for immune checkpoint inhibitor-induced inflammatory arthritis: rheumatologists versus oncologists.
Intern Med J
January 2025
Department of Rheumatology, Princess Alexandra Hospital, Brisbane, Queensland, Australia.
Background: Immune checkpoint inhibitors (ICIs) have significantly improved cancer treatment outcomes but are associated with immune-related adverse events (irAEs), such as inflammatory arthritis (ir-IA). Management of ir-IA is evolving, with corticosteroids as the primary treatment, though some cases require steroid-sparing agents.
Aims: This study aimed to compare initial mean prednisolone doses and disease persistence over 12 months in patients with rheumatoid arthritis (RA)-like ir-IA managed by rheumatologists or oncologists.
Incidence and risk factors of immune checkpoint inhibitor-induced colitis in Korean patients with cancer.
Korean J Intern Med
January 2025
Department of Internal Medicine, Kyungpook National University Hospital, Daegu, Korea.
Background/aims: Immune checkpoint inhibitors (ICIs) are effective in treating cancer. However, various immune-related adverse events (irAEs) have become prevalent, with ICI-induced colitis being the most common gastrointestinal irAE. Thus, we aimed to investigate the incidence and risk factors of ICI-induced colitis in Korean patients with cancer.
View Article and Find Full Text PDFWho is at risk for immune checkpoint inhibitor-induced colitis among Korean patients?
Korean J Intern Med
January 2025
Department of Internal Medicine, Kangwon National University College of Medicine, Chuncheon, Korea.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!